Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor–Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis

In sub-Saharan Africa, second-line ritonavir-boosted protease inhibitor–based antiretroviral therapy led to virological suppression in 69.3% of participants at week 48 and 61.5% at week 96, based on an intention-to-treat meta-analysis of 4558 participants (14 studies) and 2145 participants (8 studies), respectively.

[1]  Diederick E Grobbee,et al.  Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. , 2017, The Lancet. Infectious diseases.

[2]  C. Gilks,et al.  Second-line antiretroviral therapy: so much to be done. , 2017, The lancet. HIV.

[3]  Edward J Mills,et al.  Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. , 2017, The lancet. HIV.

[4]  G. Maartens,et al.  Resistance matters in EARNEST. , 2017, The lancet. HIV.

[5]  T. F. Rinke de Wit,et al.  Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya , 2017, AIDS.

[6]  P. Easterbrook,et al.  Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial , 2017, The lancet. HIV.

[7]  R. Shafer,et al.  Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study , 2016, The Lancet. Infectious diseases.

[8]  M. Fox,et al.  Treatment outcomes of over 1000 patients on second‐line, protease inhibitor‐based antiretroviral therapy from four public‐sector HIV treatment facilities across Johannesburg, South Africa , 2016, Tropical medicine & international health : TM & IH.

[9]  T. F. Rinke de Wit,et al.  Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. , 2016, The Journal of antimicrobial chemotherapy.

[10]  T. F. Rinke de Wit,et al.  Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. , 2016, The Journal of infectious diseases.

[11]  M. Fox,et al.  Intensive adherence counselling for HIV‐infected individuals failing second‐line antiretroviral therapy in Johannesburg, South Africa , 2016, Tropical medicine & international health : TM & IH.

[12]  G. Maartens,et al.  Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy. , 2016, International journal of antimicrobial agents.

[13]  D. Cooper,et al.  Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study. , 2016, AIDS research and human retroviruses.

[14]  M. Peeters,et al.  Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa. , 2016, AIDS research and human retroviruses.

[15]  J. Mellors,et al.  Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. , 2016, The lancet. HIV.

[16]  R. Redfield,et al.  HIV drug Resistance Mutations among Patients Failing Second-Line Antiretroviral Therapy in Rwanda , 2016, Antiviral therapy.

[17]  N. Ford,et al.  The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study. , 2016, The lancet. HIV.

[18]  J. Farrar,et al.  High prevalence of PI resistance in patients failing second-line ART in Vietnam , 2015, The Journal of antimicrobial chemotherapy.

[19]  S. Sundar,et al.  Outcome of patients on second line antiretroviral therapy under programmatic condition in India , 2015, BMC Infectious Diseases.

[20]  E. Delaporte,et al.  Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa , 2015, AIDS.

[21]  T. F. Rinke de Wit,et al.  Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  M. Egger,et al.  Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. , 2015, The lancet. HIV.

[23]  J. Xie,et al.  Week 120 Efficacy of Tenofovir, Lamivudine and Lopinavir/r-Based Second-Line Antiretroviral Therapy in Treatment-Experienced HIV Patients , 2015, PLoS ONE.

[24]  D. Cooper,et al.  Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection , 2015, PloS one.

[25]  Ning Li,et al.  Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials , 2015, Scientific Reports.

[26]  K. Ruxrungtham,et al.  Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. , 2015, The lancet. HIV.

[27]  N. Ford,et al.  Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysis. , 2014, The lancet. HIV.

[28]  P. Easterbrook,et al.  Assessment of second-line antiretroviral regimens for HIV therapy in Africa. , 2014, The New England journal of medicine.

[29]  R. Redfield,et al.  Long-Term Outcome of Second-Line Antiretroviral Therapy in Resource-Limited Settings , 2014, Journal of the International Association of Providers of AIDS Care.

[30]  A. Phillips,et al.  Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch , 2013, The Journal of infectious diseases.

[31]  I. Adewole,et al.  Optimizing Treatment Switch for Virologic Failure during First-Line Antiretroviral Therapy in Resource-Limited Settings , 2013, Journal of the International Association of Providers of AIDS Care.

[32]  D. Cooper,et al.  Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferio , 2013, The Lancet.

[33]  A. Wensing,et al.  Sustained Virological Response on Second-Line Antiretroviral Therapy following Virological Failure in HIV-Infected Patients in Rural South Africa , 2013, PloS one.

[34]  Till Bärnighausen,et al.  Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV Treatment , 2013, Science.

[35]  V. Calvez,et al.  Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. , 2012, The Journal of antimicrobial chemotherapy.

[36]  O. Laeyendecker,et al.  Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. , 2012, AIDS research and human retroviruses.

[37]  J. Nachega,et al.  Second-Line Antiretroviral Therapy: Long-Term Outcomes in South Africa , 2012, Journal of acquired immune deficiency syndromes.

[38]  M. Egger,et al.  Tenofovir in Second-Line ART in Zambia and South Africa: Collaborative Analysis of Cohort Studies , 2012, Journal of acquired immune deficiency syndromes.

[39]  T. F. Rinke de Wit,et al.  Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. , 2012, The Journal of infectious diseases.

[40]  T. F. Rinke de Wit,et al.  Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  A. Phillips,et al.  Second-Line Antiretroviral Therapy in a Workplace and Community-Based Treatment Programme in South Africa: Determinants of Virological Outcome , 2012, PloS one.

[42]  K. Freedberg,et al.  Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa , 2012, PloS one.

[43]  A. Wensing,et al.  Accumulation of Drug Resistance and Loss of Therapeutic Options Precede Commonly Used Criteria for Treatment Failure in HIV-1 Subtype-C-Infected Patients , 2012, Antiviral therapy.

[44]  T. F. Rinke de Wit,et al.  Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa , 2011, Journal of acquired immune deficiency syndromes.

[45]  L. Ferradini,et al.  High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia , 2011, Journal of the International AIDS Society.

[46]  J. Mellors,et al.  Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa , 2010, AIDS research and treatment.

[47]  J. Eron,et al.  Second‐line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline * , 2010, HIV medicine.

[48]  N. Parkin,et al.  The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.

[49]  M. Kamya,et al.  Three-Year Outcome Data of Second-Line Antiretroviral Therapy in Ugandan Adults: Good Virological Response but High Rate of Toxicity , 2009, Journal of the International Association of Physicians in AIDS Care.

[50]  Tommy F. Liu,et al.  Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  Rebecca Hoh,et al.  Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. , 2005, The Journal of infectious diseases.

[52]  Steven C Johnson,et al.  Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[54]  G. Robbins,et al.  Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial. , 2015, The lancet. HIV.

[55]  L. Ferradini,et al.  HIV-1 Protease Inhibitors Resistance Profiles in Patients with Virological Failure on LPV/r-based 2nd Line Regimen in Cambodia , 2013 .

[56]  D. Schopflocher,et al.  Development of a quality appraisal tool for case series studies using a modified Delphi technique , 2012 .

[57]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[58]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.